NSG 533 Advanced Pharmacology Final
Exam Review 2026 | Complete Solution
Guide | 100% Verified | A+ Graded
Question 1
Which statement correctly distinguishes between pharmacokinetics and
pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what
the body does to the drug.
B. Pharmacokinetics is the movement of drug across the cell membrane;
pharmacodynamics is the study of drug excretion.
C. Pharmacokinetics is what the body does to the drug; pharmacodynamics is
what the drug does to the body.
D. Pharmacokinetics only involves drug absorption; pharmacodynamics only
involves drug metabolism.
Answer: C. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body.
Rationale: Pharmacokinetics refers to the processes of drug absorption,
distribution, metabolism, and excretion (ADME) — what the body does to the
drug. Pharmacodynamics refers to the biochemical and physiologic effects of the
drug and its mechanism of action — what the drug does to the body.
Question 2
Which of the four major pharmacokinetic processes is the primary determinant of
how quickly a drug reaches its site of action?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Answer: D. Absorption
,Rationale: Absorption is the movement of a drug from its administration site into
the bloodstream. It is the primary determinant of how quickly a drug reaches its
site of action. Factors affecting absorption include route of administration, drug
formulation, blood flow, and drug solubility.
Question 3
A drug with high first-pass metabolism will have:
A. Low oral bioavailability
B. High oral bioavailability
C. Increased duration of action
D. Decreased protein binding
Answer: A. Low oral bioavailability
Rationale: First-pass metabolism refers to the extensive metabolism of a drug in
the liver before it reaches systemic circulation. Drugs with high first-pass
metabolism have significantly reduced oral bioavailability, requiring higher oral
doses or alternative routes of administration (e.g., sublingual, intravenous).
Question 4
The volume of distribution (Vd) of a drug is best described as:
A. The actual volume of blood in the body
B. The apparent volume into which a drug distributes
C. The volume of the liver
D. The total body water volume
Answer: B. The apparent volume into which a drug distributes
Rationale: Volume of distribution is a theoretical concept that describes the
apparent space in the body available to contain the drug. A large Vd indicates
extensive tissue binding and distribution, while a small Vd indicates confinement
to the vascular compartment. Vd helps determine loading dose requirements.
Question 5
,A patient with cirrhosis and hypoalbuminemia is prescribed a highly protein-bound
medication. What effect would this have on the drug's pharmacologic activity?
A. Decreased free drug concentration
B. Increased free drug concentration with enhanced effect and toxicity risk
C. No change in drug activity
D. Decreased drug metabolism
Answer: B. Increased free drug concentration with enhanced effect and toxicity
risk
Rationale: Hypoalbuminemia reduces available protein-binding sites, increasing
the free (unbound) fraction of highly protein-bound drugs. Only the free fraction is
pharmacologically active. This can lead to enhanced drug effects and increased
risk of toxicity at standard doses.
Question 6
The cytochrome P450 (CYP450) enzyme system is primarily responsible for:
A. Drug absorption
B. Phase I drug metabolism
C. Drug excretion
D. Drug distribution
Answer: B. Phase I drug metabolism
Rationale: The CYP450 enzyme system, located primarily in the liver, is
responsible for Phase I drug metabolism reactions (oxidation, reduction,
hydrolysis). These reactions typically convert lipophilic drugs into more polar,
water-soluble metabolites that can be more readily excreted.
Question 7
A patient is started on a medication that is a strong CYP3A4 inhibitor. Which of
the following is the MOST significant concern?
A. Decreased effectiveness of all medications
B. Increased serum levels of drugs metabolized by CYP3A4
, C. Increased renal excretion of drugs
D. Decreased protein binding of other drugs
Answer: B. Increased serum levels of drugs metabolized by CYP3A4
Rationale: CYP3A4 is responsible for metabolizing approximately 50% of all
medications. Inhibition of CYP3A4 reduces the metabolism of substrate drugs,
leading to increased serum levels and potential toxicity. Close monitoring and dose
adjustments are essential.
Question 8
The half-life (t½) of a drug is defined as:
A. The time required for the drug to reach steady state
B. The time required for the serum concentration to decrease by 50%
C. The time required for complete drug elimination
D. The time required for the drug to be absorbed
Answer: B. The time required for the serum concentration to decrease by 50%
Rationale: Half-life is the time required for the serum concentration of a drug to
decrease by 50%. It is a key pharmacokinetic parameter that determines dosing
intervals and the time required to reach steady state (approximately 4-5 half-lives).
Question 9
Steady state of a drug is typically achieved after:
A. 1-2 half-lives
B. 4-5 half-lives
C. 7-10 half-lives
D. 24 hours
Answer: B. 4-5 half-lives
Rationale: Steady state is reached when the rate of drug administration equals the
rate of drug elimination. This typically occurs after approximately 4-5 half-lives of
continuous dosing. At this point, drug concentrations fluctuate within a predictable
range.
Exam Review 2026 | Complete Solution
Guide | 100% Verified | A+ Graded
Question 1
Which statement correctly distinguishes between pharmacokinetics and
pharmacodynamics?
A. Pharmacokinetics is what the drug does to the body; pharmacodynamics is what
the body does to the drug.
B. Pharmacokinetics is the movement of drug across the cell membrane;
pharmacodynamics is the study of drug excretion.
C. Pharmacokinetics is what the body does to the drug; pharmacodynamics is
what the drug does to the body.
D. Pharmacokinetics only involves drug absorption; pharmacodynamics only
involves drug metabolism.
Answer: C. Pharmacokinetics is what the body does to the drug;
pharmacodynamics is what the drug does to the body.
Rationale: Pharmacokinetics refers to the processes of drug absorption,
distribution, metabolism, and excretion (ADME) — what the body does to the
drug. Pharmacodynamics refers to the biochemical and physiologic effects of the
drug and its mechanism of action — what the drug does to the body.
Question 2
Which of the four major pharmacokinetic processes is the primary determinant of
how quickly a drug reaches its site of action?
A. Distribution
B. Metabolism
C. Excretion
D. Absorption
Answer: D. Absorption
,Rationale: Absorption is the movement of a drug from its administration site into
the bloodstream. It is the primary determinant of how quickly a drug reaches its
site of action. Factors affecting absorption include route of administration, drug
formulation, blood flow, and drug solubility.
Question 3
A drug with high first-pass metabolism will have:
A. Low oral bioavailability
B. High oral bioavailability
C. Increased duration of action
D. Decreased protein binding
Answer: A. Low oral bioavailability
Rationale: First-pass metabolism refers to the extensive metabolism of a drug in
the liver before it reaches systemic circulation. Drugs with high first-pass
metabolism have significantly reduced oral bioavailability, requiring higher oral
doses or alternative routes of administration (e.g., sublingual, intravenous).
Question 4
The volume of distribution (Vd) of a drug is best described as:
A. The actual volume of blood in the body
B. The apparent volume into which a drug distributes
C. The volume of the liver
D. The total body water volume
Answer: B. The apparent volume into which a drug distributes
Rationale: Volume of distribution is a theoretical concept that describes the
apparent space in the body available to contain the drug. A large Vd indicates
extensive tissue binding and distribution, while a small Vd indicates confinement
to the vascular compartment. Vd helps determine loading dose requirements.
Question 5
,A patient with cirrhosis and hypoalbuminemia is prescribed a highly protein-bound
medication. What effect would this have on the drug's pharmacologic activity?
A. Decreased free drug concentration
B. Increased free drug concentration with enhanced effect and toxicity risk
C. No change in drug activity
D. Decreased drug metabolism
Answer: B. Increased free drug concentration with enhanced effect and toxicity
risk
Rationale: Hypoalbuminemia reduces available protein-binding sites, increasing
the free (unbound) fraction of highly protein-bound drugs. Only the free fraction is
pharmacologically active. This can lead to enhanced drug effects and increased
risk of toxicity at standard doses.
Question 6
The cytochrome P450 (CYP450) enzyme system is primarily responsible for:
A. Drug absorption
B. Phase I drug metabolism
C. Drug excretion
D. Drug distribution
Answer: B. Phase I drug metabolism
Rationale: The CYP450 enzyme system, located primarily in the liver, is
responsible for Phase I drug metabolism reactions (oxidation, reduction,
hydrolysis). These reactions typically convert lipophilic drugs into more polar,
water-soluble metabolites that can be more readily excreted.
Question 7
A patient is started on a medication that is a strong CYP3A4 inhibitor. Which of
the following is the MOST significant concern?
A. Decreased effectiveness of all medications
B. Increased serum levels of drugs metabolized by CYP3A4
, C. Increased renal excretion of drugs
D. Decreased protein binding of other drugs
Answer: B. Increased serum levels of drugs metabolized by CYP3A4
Rationale: CYP3A4 is responsible for metabolizing approximately 50% of all
medications. Inhibition of CYP3A4 reduces the metabolism of substrate drugs,
leading to increased serum levels and potential toxicity. Close monitoring and dose
adjustments are essential.
Question 8
The half-life (t½) of a drug is defined as:
A. The time required for the drug to reach steady state
B. The time required for the serum concentration to decrease by 50%
C. The time required for complete drug elimination
D. The time required for the drug to be absorbed
Answer: B. The time required for the serum concentration to decrease by 50%
Rationale: Half-life is the time required for the serum concentration of a drug to
decrease by 50%. It is a key pharmacokinetic parameter that determines dosing
intervals and the time required to reach steady state (approximately 4-5 half-lives).
Question 9
Steady state of a drug is typically achieved after:
A. 1-2 half-lives
B. 4-5 half-lives
C. 7-10 half-lives
D. 24 hours
Answer: B. 4-5 half-lives
Rationale: Steady state is reached when the rate of drug administration equals the
rate of drug elimination. This typically occurs after approximately 4-5 half-lives of
continuous dosing. At this point, drug concentrations fluctuate within a predictable
range.
